Despite the growing number of AD patients, currently, only four drugs and one combined treatment are approved by the FDA and authorized by the European Union [45], which are donepezil, galantamine, and rivastigmine, three acetylcholinesterase (AChE) inhibitors, and memantine, an N-methyl-D-aspartate receptor antagonist. This evidence concerns the gene ACHE and Alzheimer disease.